Immuneering Corp
IMRXNext catalyst
IMM-1-104 Monotherapy (Treatment Group A)
Advanced Solid Tumor
Get an email about IMRX's next catalysts
Track Immuneering (IMRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
IMRX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.29 | FQ end Sep/2026 | Call: tbd
IMM-1-104 Monotherapy (Treatment Group A) Phase 2 Est. Readout
Estimated primary completion for IMM-1-104 Monotherapy (Treatment Group A) trial (NCT05585320) in Advanced Solid Tumor. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Atebimetinib
Pancreatic Cancer
mGnP
Pancreatic Cancer
IMM-6-415
Advanced Solid Tumor (Phase 1)
IMM-1-104 + pembrolizumab (Treatment Group E)
Advanced Solid Tumor
IMM-1-104 + dabrafenib (Treatment Group D)
Advanced Solid Tumor
IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
Advanced Solid Tumor
IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
Advanced Solid Tumor
IMM-1-104 Monotherapy (Treatment Group A)
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Atebimetinib | Phase 3 | Pancreatic Cancer | - | - |
mGnP | Phase 3 | Pancreatic Cancer | - | - |
IMM-6-415 | Phase 2 | Advanced Solid Tumor (Phase 1) | - | - |
IMM-1-104 + pembrolizumab (Treatment Group E) | Phase 2 | Advanced Solid Tumor | - | - |
IMM-1-104 + dabrafenib (Treatment Group D) | Phase 2 | Advanced Solid Tumor | - | - |
IMM-1-104 + modified FOLFIRINOX (Treatment Group C) | Phase 2 | Advanced Solid Tumor | - | - |
IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) | Phase 2 | Advanced Solid Tumor | - | - |
IMM-1-104 Monotherapy (Treatment Group A) | Phase 2 | Advanced Solid Tumor | - | - |
Frequently asked questions
What is in Immuneering Corp's drug pipeline?→
CatalystAlert tracks 8 drug candidates in Immuneering Corp's (IMRX) pipeline across Phase 3, Phase 2. Its lead program is Atebimetinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immuneering Corp's next FDA catalyst?→
Immuneering Corp's (IMRX) next tracked catalyst is a Phase 2 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMRX biotech catalysts?→
Add IMRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immuneering Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.